Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

News
Article

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

A series of test tubes in a laboratory. Image credit: ©Vladislava – stock.adobe.com

Novartis will cease development of the GT005 programme. Image credit: ©Vladislava – stock.adobe.com

In a news release, healthcare investment trust Syncona Ltd announced that pharmaceutical company Novartis would discontinue development of GT005. The decision was based on a recommendation from the Independent Data Monitoring Committee, based on data from the Phase II HORIZON study. GT005 was under development for addressing geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).1

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022. According to the statement from Syncona, the Independent Data Monitoring Committee performed an “overall benefit risk assessment of available data from the programme studies.” The committee concluded that the available data did not support continuation of development for GT005.

Chris Hollowood, CEO of Syncona Investment Management Limited, addressed the news in the company’s press statement. “We are naturally disappointed for patients following the decision to discontinue GT005, but we respect Novartis’ decision,” he wrote. “We remain focussed on our strategy of building and maintaining our portfolio of companies providing significant opportunities to deliver strong risk-adjusted returns to our shareholders and to make a difference to the lives of patients with devastating diseases.”

Syncona received upfront cash proceeds of £326 million ($442 million) for its holding in Gyroscope. Additional Gyroscope milestone payments will be written off, in a negative £54.5 million valuation impact, the company said.


Reference

  1. Update on Gyroscope and associated milestone payments. News release. Syncona Ltd. Published 11 September 2023, accessed 12 September 2023.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.